(Q36704848)

15 August 2017

1 reference

title

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues (English)

1 reference

15 August 2017

1 reference

Radermecker RP

1

1 reference

15 August 2017

Scheen AJ

series ordinal

2

1 reference

15 August 2017

publication date

1 July 2007

1 reference

Diabetes - Metabolism: Research and Reviews

15 August 2017

published in

1 reference

15 August 2017

volume

23

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

348-355

1 reference

Immunogenicity and allergenic potential of animal and human insulins

15 August 2017

cites work

1 reference

Immunologic Reactions to Insulin: Insulin Allergy, Insulin Resistance, and the Autoimmune Insulin Syndrome

21 January 2018

1 reference

Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes

21 January 2018

1 reference

7 January 2021

Insulin pump therapy: a meta-analysis

1 reference

7 January 2021

Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis

1 reference

7 January 2021

Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness

1 reference

7 January 2021

1 reference

7 January 2021

A critical appraisal of the role of insulin analogues in the management of diabetes mellitus

1 reference

7 January 2021

Dermal reactions to insulin therapy

1 reference

7 January 2021

The incidence of skin reactivity to insulin in diabetic patients

1 reference

7 January 2021

1 reference

7 January 2021

Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates

1 reference

7 January 2021

Monomeric insulins and their experimental and clinical implications

1 reference

7 January 2021

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

1 reference

7 January 2021

The human insulin analog aspart can induce insulin allergy

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

7 January 2021

A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine

1 reference

7 January 2021

Hypersensitivity to insulin

1 reference

7 January 2021

A rational clinical approach to suspected insulin allergy: status after five years and 22 cases.

1 reference

7 January 2021

Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology

1 reference

7 January 2021

Human insulin allergy-immediate and late type III reactions in a long-standing IDDM patient

1 reference

7 January 2021

Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill (Penfill R)

1 reference

7 January 2021

Insulin-induced drug eruptions and reliability of skin tests

1 reference

7 January 2021

Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions

1 reference

7 January 2021

Insulin-injection-site reactions associated with type I latex allergy

1 reference

7 January 2021

Physical Stability of Insulin Formulations

1 reference

7 January 2021

Interaction between plastic catheter tubings and regular insulin preparations used for continuous subcutaneous insulin-infusion therapy

1 reference

7 January 2021

Insulin compatibility with polymer materials used in external pump infusion systems

1 reference

7 January 2021

Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity

1 reference

7 January 2021

Generalized allergy due to zinc and protamine in insulin preparation treated with insulin pump

1 reference

7 January 2021

CSII in management of insulin allergy

1 reference

7 January 2021

Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion

1 reference

7 January 2021

Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin

1 reference

7 January 2021

Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes

1 reference

7 January 2021

Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes

1 reference

7 January 2021

Lispro analog for treatment of generalized allergy to human insulin

1 reference

7 January 2021

Lispro in the treatment of insulin allergy

1 reference

7 January 2021

Insulin lispro, an alternative in insulin hypersensitivity

1 reference

7 January 2021

Immediate hypersensitivity to ceftriaxone

1 reference

7 January 2021

A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-acting insulin

1 reference

7 January 2021

The insulin analog aspart: a safe alternative in insulin allergy

1 reference

7 January 2021

Human insulin analog insulin aspart does not cause insulin allergy

1 reference

7 January 2021

Successful treatment of insulin allergy in a 1-year-old infant with neonatal diabetes by lispro and glargine insulin

1 reference

7 January 2021

Systemic allergic reaction by a human insulin analog

1 reference

7 January 2021

Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering

1 reference

7 January 2021

Insulin allergy and immunologic insulin resistance caused by interleukin-6 in a patient with lung cancer

1 reference

7 January 2021

Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion.

1 reference

7 January 2021

The human insulin analogue aspart is not the almighty solution for insulin allergy

1 reference

7 January 2021

Desensitization-resistant insulin allergy

1 reference

7 January 2021

Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes.

1 reference

7 January 2021

Glargine insulin is not an alternative in insulin allergy

1 reference

7 January 2021

Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion

1 reference

7 January 2021

Type III allergy to insulin detemir

1 reference

7 January 2021

Stability of insulin lispro in insulin infusion systems.

1 reference

7 January 2021

In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.

1 reference

7 January 2021

Insulin desensitization with insulin lispro and an insulin pump in a 5-year-old child

1 reference

7 January 2021

Localized insulin allergy treated with continuous subcutaneous insulin

1 reference

7 January 2021

Continuous subcutaneous insulin infusion to resolve an allergy to human insulin

1 reference

7 January 2021

Allergy to insulin in a woman with gestational diabetes mellitus: transient efficiency of continuous subcutaneous insulin lispro infusion

1 reference

7 January 2021

Successful Treatment of Insulin Allergy in a Type 1 Diabetic Patient by Means of Constant Subcutaneous Pump Infusion of Insulin

1 reference

7 January 2021

Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.714

1 reference

15 August 2017

1 reference